{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:08:24Z","timestamp":1791486504343,"version":"4.3.4"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1097\/xeb.0000000000000048","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T13:34:20Z","timestamp":1435671260000},"page":"3-14","source":"Crossref","is-referenced-by-count":11,"title":["Control of invasive meningococcal disease"],"prefix":"10.1097","volume":"14","author":[{"given":"Helen","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210130","first-page":"1","article-title":"National Center for Infectious Diseases (CDC), PreventionPrevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R2-2-20210130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/clinids\/5.1.71","article-title":"Meningococcal disease: still with us.","volume":"5","author":"Peltola","year":"1983","journal-title":"Rev Infect Dis"},{"key":"R3-2-20210130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe.","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"R4-2-20210130","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1542\/peds.2008-0581","article-title":"Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study.","volume":"123","author":"Borg","year":"2009","journal-title":"Pediatrics"},{"key":"R5-2-20210130","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/hv.7.4.14434","article-title":"Cost impact of complications in meningococcal disease: evidence from a United States managed care population.","volume":"7","author":"Davis","year":"2011","journal-title":"Hum Vaccin"},{"key":"R6-2-20210130","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.ehrm.2011.08.001","article-title":"Costs of sequelae associated with invasive meningococcal disease: findings from a US managed care population.","volume":"2","author":"Karve","year":"2011","journal-title":"Health Outcomes Res Med"},{"key":"R7-2-20210130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/INF.0000000000000043","article-title":"The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children.","volume":"33","author":"Wang","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R10-2-20210130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0009922809347797","article-title":"Epidemiology and meningococcal serogroup distribution in the United States.","volume":"49","author":"Hershey","year":"2010","journal-title":"Clin Pediatr"},{"key":"R11-2-20210130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1179\/016164110X12644252260754","article-title":"Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention.","volume":"32","author":"Safadi","year":"2010","journal-title":"Neurol Res"},{"issue":"Supplement","key":"R12-2-20210130","first-page":"S50","article-title":"Vaccine preventable diseases and vaccination coverage in Australia, 2005 to 2007.","volume":"34","author":"Chiu","year":"2010","journal-title":"Commun Dis Intell Q Rep"},{"key":"R14-2-20210130","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"key":"R15-2-20210130","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 2","key":"R17-2-20210130","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R18-2-20210130","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease.","volume":"30S","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"R19-2-20210130","first-page":"E224","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2012.","volume":"37","author":"Lahra","year":"2013","journal-title":"Commun Dis Intell Q Rep"},{"key":"R20-2-20210130","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/0140-6736(91)91112-8","article-title":"Influenza A and meningococcal disease.","volume":"338","author":"Cartwright","year":"1991","journal-title":"Lancet"},{"key":"R21-2-20210130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5694\/j.1326-5377.1991.tb94004.x","article-title":"Epidemic meningococcal meningitis in central Australia in the 1970s.","volume":"155","author":"Creasey","year":"1991","journal-title":"Med J Aust"},{"key":"R23-2-20210130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5694\/j.1326-5377.1993.tb121793.x","article-title":"Epidemic meningococcal meningitis in central Australia, 1987-1991.","volume":"158","author":"Patel","year":"1993","journal-title":"Med J Aust"},{"key":"R24-2-20210130","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/archdischild-2012-302036","article-title":"Prospects for eradication of meningococcal disease.","volume":"97","author":"Nadel","year":"2012","journal-title":"Arch Dis Child"},{"key":"R25-2-20210130","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.4161\/hv.21794","article-title":"Meningococcal serogroup Y emergence in Europe: update 2011.","volume":"8","author":"Broker","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R26-2-20210130","first-page":"18","article-title":"Invasive meningococcal infections (England and Wales): annual report for 201112.","volume":"7","year":"2013","journal-title":"Health Protect Rep"},{"key":"R27-2-20210130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger.","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R29-2-20210130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study.","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"R30-2-20210130","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"Members of Canadian Immunization Monitoring Program, Active (IMPACT). The disease burden of invasive meningococcal serogroup B disease in Canada.","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R31-2-20210130","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1542\/peds.95.5.646","article-title":"Adverse outcomes of bacterial meningitis in school-age survivors.","volume":"95","author":"Grimwood","year":"1995","journal-title":"Pediatrics"},{"key":"R32-2-20210130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/pubmed\/fdp075","article-title":"Invasive meningococcal disease: improving management through structured review of cases in the Hunter New England area, Australia.","volume":"32","author":"Guimont","year":"2010","journal-title":"J Public Health (Oxf)"},{"key":"R33-2-20210130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S0022172400063828","article-title":"Meningococcal disease in South Australia: incidence and serogroup distribution 1971-1980.","volume":"90","author":"Hansman","year":"1983","journal-title":"J Hyg (Lond)"},{"key":"R34-2-20210130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1440-1754.1999.t01-1-00337.x","article-title":"Invasive meningococcal infection in Western Australia.","volume":"35","author":"Olesch","year":"1999","journal-title":"J Paediatr Child Health"},{"key":"R35-2-20210130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1471-2334-10-232","article-title":"Predicting sequelae and death after bacterial meningitis in childhood: a systematic review of prognostic studies.","volume":"10","author":"de Jonge","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R36-2-20210130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1136\/bmj.332.7553.1299","article-title":"Effectiveness of antibiotics given before admission in reducing mortality from meningococcal disease: systematic review.","volume":"332","author":"Hahne","year":"2006","journal-title":"Br Med J (Clin Res ed)"},{"key":"R37-2-20210130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/PCC.0b013e3181ae785a","article-title":"Longer-term psychiatric adjustment of children and parents after meningococcal disease.","volume":"10","author":"Garralda","year":"2009","journal-title":"Pediatr Crit Care Med"},{"key":"R38-2-20210130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/322024","article-title":"Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.","volume":"184","author":"Borrow","year":"2001","journal-title":"J Infect Dis"},{"key":"R39-2-20210130","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1172\/JCI108235","article-title":"Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.","volume":"56","author":"Gold","year":"1975","journal-title":"J Clin Invest"},{"key":"R40-2-20210130","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1365-3156.2007.01929.x","article-title":"Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci.","volume":"12","author":"Dellicour","year":"2007","journal-title":"Trop Med Int Health"},{"key":"R41-2-20210130","first-page":"14","article-title":"ACIP): prevention and control of meningococcal disease.","volume":"62","year":"2013","journal-title":"Morb Mortal Wkly Rep"},{"key":"R42-2-20210130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.","volume":"326","author":"Ramsay","year":"2003","journal-title":"Br Med J (Clin Res ed)"},{"key":"R43-2-20210130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R45-2-20210130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/1471-2334-13-576","article-title":"Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination.","volume":"13","author":"Collard","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R46-2-20210130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study.","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"R47-2-20210130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines.","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"R48-2-20210130","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1172\/JCI109383","article-title":"Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.","volume":"63","author":"Zollinger","year":"1979","journal-title":"J Clin Invest"},{"key":"R49-2-20210130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"R50-2-20210130","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/IAI.65.3.1053-1060.1997","article-title":"Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.","volume":"65","author":"Zollinger","year":"1997","journal-title":"Infect Immun"},{"key":"R51-2-20210130","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1128\/IAI.01424-06","article-title":"Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.","volume":"75","author":"Williams","year":"2007","journal-title":"Infect Immun"},{"key":"R52-2-20210130","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1084\/jem.138.5.1156","article-title":"Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis.","volume":"138","author":"Devoe","year":"1973","journal-title":"J Exp Med"},{"key":"R53-2-20210130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"R54-2-20210130","first-page":"1","article-title":"Annual report of the Australian Meningococcal Surveillance Programme, 2007 - Amended.","volume":"33","author":"Tapsall","year":"2009","journal-title":"Commun Dis Intell Q Rep"},{"key":"R55-2-20210130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R56-2-20210130","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4161\/hv.3.5.4458","article-title":"Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006.","volume":"3","author":"McNicholas","year":"2007","journal-title":"Hum Vaccin"},{"key":"R57-2-20210130","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"key":"R58-2-20210130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/ije\/dyn228","article-title":"Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.","volume":"38","author":"Galloway","year":"2009","journal-title":"Int J Epidemiol"},{"key":"R59-2-20210130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1586\/erv.10.116","article-title":"Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.","volume":"9","author":"Bai","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"R63-2-20210130","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles.","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"R64-2-20210130","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R65-2-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"R66-2-20210130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"R68-2-20210130","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB.","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R70-2-20210130","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R71-2-20210130","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"R73-2-20210130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease.","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"R74-2-20210130","first-page":"837","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn Expert Rev V","volume":"12","author":"Martin","year":"2013","journal-title":"accines"},{"key":"R75-2-20210130","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection: serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R76-2-20210130","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"R77-2-20210130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1699-0463.1991.tb01258.x","article-title":"Immunization against serogroup B meningococci. Opsonin response in vaccinees as measured by chemiluminescence.","volume":"99","author":"Lehmann","year":"1991","journal-title":"APMIS"},{"key":"R78-2-20210130","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/IAI.67.5.2552-2560.1999","article-title":"Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.","volume":"67","author":"Lehmann","year":"1999","journal-title":"Infect Immun"},{"key":"R79-2-20210130","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1128\/IAI.67.12.6526-6532.1999","article-title":"Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes.","volume":"67","author":"Lehmann","year":"1999","journal-title":"Infect Immun"},{"key":"R80-2-20210130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/mpat.1999.0296","article-title":"Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay.","volume":"27","author":"Ison","year":"1999","journal-title":"Microb Pathog"},{"key":"R81-2-20210130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.","volume":"307","author":"Gossger","year":"2012","journal-title":"J Am Med Assoc"},{"key":"R82-2-20210130","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R83-2-20210130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"R84-2-20210130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","article-title":"Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R85-2-20210130","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccines"},{"key":"R89-2-20210130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R91-2-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0140-6736(92)92411-8","article-title":"Herd immunity and the meningococcal vaccine trial in Norway.","volume":"340","author":"Bjune","year":"1992","journal-title":"Lancet"},{"key":"R92-2-20210130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/514232","article-title":"Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.","volume":"177","author":"Perkins","year":"1998","journal-title":"J Infect Dis"},{"key":"R94-2-20210130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.","volume":"31","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R95-2-20210130","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"R96-2-20210130","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"R97-2-20210130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase 12 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R98-2-20210130","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R99-2-20210130","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase \u00bd trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants.","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"R101-2-20210130","first-page":"1113","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa V","volume":"31","author":"Hong","year":"2013","journal-title":"accine"},{"key":"R106-2-20210130","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0140-6736(13)61924-8","article-title":"Immunisation against meningococcus B.","volume":"382","author":"Head","year":"2013","journal-title":"Lancet"},{"key":"R107-2-20210130","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.","volume":"31","author":"Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"R109-2-20210130","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"R110-2-20210130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.vaccine.2013.11.042","article-title":"Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines.","volume":"32","author":"Marshall","year":"2014","journal-title":"Vaccine"},{"key":"R111-2-20210130","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.vaccine.2014.04.046","article-title":"The missing link: family physician perspectives on barriers and enablers to prescribing non-funded vaccines.","volume":"32","author":"Taylor","year":"2014","journal-title":"Vaccine"},{"key":"R112-2-20210130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(14)60226-9","article-title":"Group B meningococcal vaccine: recommendations for UK use.","volume":"383","author":"Pollard","year":"2014","journal-title":"Lancet"}],"container-title":["International Journal of Evidence-Based Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/XEB.0000000000000048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T04:21:40Z","timestamp":1652674900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01787381-201603000-00002"}},"subtitle":["is it achievable?"],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/xeb.0000000000000048","relation":{},"ISSN":["1744-1609"],"issn-type":[{"value":"1744-1609","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}